Essential Partners’s Rigel Pharmaceuticals RIGL Stock Holding History

Essential Partners’s Portfolio RIGL Stock Details RIGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$193	Hold	4	–	–	﹤0.01%	2606
2026 Q2	$156	Hold	4	–	–	﹤0.01%	2684
2026 Q1	$108	Sell	4 -6	-60%	-$202	﹤0.01%	2707
2025 Q4	$428	Buy	10 +7	+233%	+$264	﹤0.01%	2258
2025 Q3	$85	Hold	3	–	–	﹤0.01%	2511
2025 Q2	$56	Buy	+3	New	+$57	﹤0.01%	2142

Other funds holding RIGL

HWAM

Hennion & Walsh Asset Management Parsippany, New Jersey $3.42B AUM 25.82% 1-Year Est. Return

Venture Visionary Partners Sylvania, Ohio $3.82B AUM 21.33% 1-Year Est. Return

JWS

Juncture Wealth Strategies Scottsdale, Arizona $390M AUM 19.15% 1-Year Est. Return

Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return

GWM

GK Wealth Management Reno, Nevada $178M AUM 41.48% 1-Year Est. Return

VCM

Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return

TCM

Triumph Capital Management Denver, Colorado $573M AUM 15.32% 1-Year Est. Return

TWD

True Wealth Design Akron, Ohio $426M AUM 16.34% 1-Year Est. Return

Essential Partners's RIGL Position: Q3 2026 in Review

Essential Partners held its Rigel Pharmaceuticals (RIGL) position steady in Q3 2026 at 4 shares worth $193. The position accounts for ﹤0.01% of the portfolio, ranked #2606.

Essential Partners first reported a position in RIGL in Q2 2025 and has held it in 6 quarters since. The position peaked at $428 in Q4 2025. 10 funds tracked by Wall St. Rank hold RIGL as of Q3 2026.

Essential Partners held 4 shares of Rigel Pharmaceuticals worth $193 as of Q3 2026.
Essential Partners left its Rigel Pharmaceuticals share count unchanged in Q3 2026.
Rigel Pharmaceuticals made up ﹤0.01% of Essential Partners's portfolio in Q3 2026, its #2606 holding.
Essential Partners first reported a position in Rigel Pharmaceuticals in Q2 2025 and has held it in 6 quarters since.
Essential Partners's Rigel Pharmaceuticals position peaked at $428 in Q4 2025.
10 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q3 2026.

Based on Essential Partners's 13F filing for Q3 2026, filed 14 Oct 2026.